Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Axsome Therapeutics Inc is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 93 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$40.10|
|52-week range||$19.38 - $87.24|
|50-day moving average||$30.88|
|200-day moving average||$48.38|
|Wall St. target price||$86.21|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-07)||26.34%|
|1 month (2021-09-17)||34.93%|
|3 months (2021-07-16)||-26.04%|
|6 months (2021-04-16)||-24.96%|
|1 year (2020-10-16)||-45.62%|
|2 years (2019-10-18)||90.59%|
|3 years (2018-10-18)||878.05%|
|5 years (2016-10-18)||446.32%|
|Gross profit TTM||$0|
|Return on assets TTM||-40.21%|
|Return on equity TTM||-100.7%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 3.8 million Axsome Therapeutics shares held short by investors – that's known as Axsome Therapeutics's "short interest". This figure is 12.6% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Axsome Therapeutics shares can be evaluated.
Axsome Therapeutics's "short interest ratio" (SIR) is the quantity of Axsome Therapeutics shares currently shorted divided by the average quantity of Axsome Therapeutics shares traded daily (recently around 1.1 million). Axsome Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Axsome Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.
However Axsome Therapeutics's short interest can also be evaluated against the total number of Axsome Therapeutics shares, or, against the total number of tradable Axsome Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axsome Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Axsome Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1275% of the tradable shares (for every 100,000 tradable Axsome Therapeutics shares, roughly 128 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Axsome Therapeutics.
Find out more about how you can short Axsome Therapeutics stock.
We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $19.38 up to $87.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 2.2265. This would suggest that Axsome Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Axsome Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.